CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Get Alerts CTIC Hot Sheet
Join SI Premium – FREE
SEATTLE, Oct. 14, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on October 14, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).
The employee received options to purchase 18,000 shares of CTI BioPharma common stock. The options will be issued upon the employee's grant date (the "Grant Date"), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of CTI BioPharma common stock on the Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:Maeve Conneighton/Maghan Meyers+212-600-1902[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301400626.html
SOURCE CTI BioPharma Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CUEX Metal AG and Caravelle International Group Sign Innovative Manganese Ore Purchase Agreement to Advance Wood Drying Business
- Thrivent Brings Rare Exhibition featuring the Vatican Museums' Graphics Art Collection from the Contemporary Art Collection to Minneapolis for First Ever US Appearance in Dialogue with Thrivent Art Co
- Cirba Solutions Launches "SustainABILITY 10,000" as it Commits 10,000 Hours to Sustainability Education in Local Communities
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!